Compound Library
Evidence-based research summaries across 9 categories.
Melanocortin receptor agonist (MC4R) studied for sexual dysfunction in both males and females. FDA-approved for HSDD in premenopausal women (Vyleesi).
Neuropeptide that activates GnRH release from hypothalamus. Studied in hypogonadotropic hypogonadism, sexual arousal, and reproductive axis regulation research.
Human chorionic gonadotropin — LH/CG receptor agonist. Extensively studied in hypogonadism, fertility, testosterone production, and testicular function preservation.
Neuropeptide hormone studied for social bonding, trust behavior, sexual arousal, anxiety reduction, and cardiovascular protective effects beyond reproductive function.
Full-length 54 amino acid kisspeptin — the master regulator of the HPG axis. Studied for hypogonadotropic hypogonadism, IVF triggering, and pubertal development. Kisspeptin-10 is the active C-terminal fragment.
Linear melanocortin MC1R agonist (parent to MT-II). FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP). Studied for photoprotection, tanning, and skin disorder research. Lacks the sexual side effects of MT-II.
Cyclic melanocortin peptide (same active compound as PT-141 but characterized in injectable research context). FDA-approved as Vyleesi for HSDD in premenopausal women. Studies in male sexual dysfunction ongoing.